New York Agenda - Sachs Associates

08.00
REGISTRATION & COFFEE
08.30
Opening Speech: “The Promise and Threat of Precision Cancer Medicine”
by: Barrett J. Rollins, MD, PhD Linde Family Professor of Medicine at Harvard Medical School, Chief Scientific Officer at Dana-Farber Cancer Institute
08.55
Deal Making
Co-Chaired by:
Anne Altmeyer, VP, BD & Licensing, Head Negotiation, Oncology, Novartis Pharmaceuticals
Dov Hass, Associate, Morgan, Lewis & Bockius LLP
Panellists:
Dennis Purcell, Founder and Senior Advisor, Aisling Capital LLC
Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo
Catherine Pickering, Head of Oncology Licensing, Global BD, Merck Serono Pharmaceuticals
Howard J. Fingert, Senior Medical Director, BD & Clinical Intelligence, Takeda, Inc.
Ji Li, Vice President, Business Development and Licensing, Merck Research Laboratories
09.55
10.55
NextGen Immunotherapeutics
Co-Chaired by
Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis
Panellists:
Dragan Cicic, COO and CMO, Actinium Pharmaceuticals, Inc.
Gil Beyen, Chairman and CEO, ERYTECH Pharma SA
Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer
Jeff Abbey, President and CEO, Argos Therapeutics, Inc.
Marc Mansour, CEO, Immunovaccine, Inc.
Paul Higham, Managing Director and CEO, immatics biotechnologies GmbH
Robert de Petit, Chief Scientific Officer, Advaxis, Inc.
COFFEE BREAK
Emerging Presenting Companies Track
09.05
Pelican Therapeutics
09.15
Rexahn Pharmaceuticals, Inc.
09.25
SolaranRx, Inc.
09.35
Microbial Robotics
09.45
BBS Nanotechnologies
09.55
TBA
10.05
NYU Office of Therapeutics Alliances
10.15
TBA
10.25
TBA
10.35
TBA
Presenting Companies TRACK A
11.10
12.10
13.00
Gene & Cell Therapy
Co-Chaired by:
Maxim Jacobs, Senior Healthcare Analyst, Edison Group
Mike Rice, Senior Consultant, Defined Health
Panellists:
Madhusudan Peshwa, Executive Vice President, Cellular Therapies, MaxCyte, Inc.
Robert Dillman, Vice-President, Oncology, NeoStem, Inc.
Peter Hoang, Senior Vice President BD & Strategy, Bellicum Pharmaceuticals
Peter Sandor, Vice President, Global Marketing Oncology TA, Amgen, Inc.
Personalized Medicine & Diagnostics
Co-Chaired by:
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Rowan Chapman, Managing Director, Ventures, GE Healthcare
Panellists:
Bernhard Sixt, President and CEO, ImmunID
Claudio Carini, Global Clinical Immunology and Biomarkers Lead, Pfizer
Lisa Ricciardi, SVP, Corporate & Business Development, Foundation Medicine, Inc.
Thomas Tulip, Executive Vice President and CBO, Navidea Biopharmaceuticals
11.00
Berg LLC
11.15
BerGenBio AS
11.30
Nanobiotix SA
11.45
IMMUNE Pharmaceuticals
12.00
Enumeral Biomedical Holdings, Inc.
12.15
XEME Biopharma, Inc.
12.30
TapImmune, Inc.
NETWORKING LUNCH
Presenting Companies TRACK B
Presenting Companies TRACK C
14.00
Advaxis, Inc.
Actinium Pharmaceuticals
14.15
Argos Therapeutics, Inc.
CASI Pharmaceuticals, Inc.
14.30
ERYTECH Pharma SA
MaxCyte, Inc.
14.45
Immunovaccine, Inc.
Novogen Ltd.
15.00
Navidea Biopharmaceuticals
immatics biotechnologies GmbH
15.15
NeoStem, Inc.
Cell Source Ltd.
15.30
CEL-SCI CORPORATION
ImmunID
15.45
COFFEE BREAK
16.00
Public & Private Partnerships
Co-Chaired by:
Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society
O. Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute
Panellists:
Daniel Auclair, Vice President, Translational Research, The Multiple Myeloma Research Foundation
Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche
Leigh Zawel, Site Head, New York and Boston Centers for Therapeutic Innovation, Pfizer, Inc.
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Steven Young, President & COO, Addario Lung Cancer Medical Institute
17.00
Investment Roundtable
Co-Chaired by:
Beth Jacobs, Managing Partner, Excellentia Global Partners
Stuart Barich, Managing Director, Raymond James Financial, Inc.
Panellists:
Daniel Teper, CEO, IMMUNE Pharmaceuticals
Jens Eckstein, President, SR ONE
Philippe Muaberna, CFO, Nanobiotix SA
Shakti Narayan, Sr. Director, Transactions, Johnson & Johnson
Todd Foley, Managing Director, MPM Capital LLC
18.00
NETWORKING RECEPTION
19.00
END OF THE FORUM